Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06517888Phase 1Recruiting

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Role: lead

NCT07503613Enrolling By Invitation

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Role: lead

NCT05572073Recruiting

Otoferlin Gene-mediated Hearing Loss Natural History Study

Role: lead

NCT05821959Phase 1Recruiting

Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss

Role: lead

NCT06696456Enrolling By Invitation

Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy

Role: lead

All 5 trials loaded